Sign in

MMTZF on OTC

MindMaze Therapeutics Holding SA

MindMaze Therapeutics Holding SA is a pharmaceutical preparations company, listed on OTC (MMTZF).1

Price unavailable

Last updated Oct 21, 2026.

Overview

6.3MRevenue, fiscal 20232
-98.2MNet income, fiscal 20232

Compare with AC Immune SA or Altamira Therapeutics Ltd., or pick any stock.

  • TickerMMTZF on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersV81
  • Incorporated inSwitzerland3
  • Business addressAvenue De Secheron 15, Ch-1202 Geneva3
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Our jurisdiction of incorporation is Switzerland, and our registered office is in Geneva, Canton of Geneva, Switzerland. A majority of our outstanding securities that are registered in our share register are owned by non-U.S. residents. Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are currently eligible for treatment as a foreign private issuer. As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. domestic issuers whose securities are registered under the Securities Exchange Act of 1934, as amended, referred to herein as the Exchange Act.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CHF, the currency the company reports in.

Key numbers, fiscal 2023

-1751.4%Operating margin2
-1551.5%Net margin2
-11.0%Revenue growth, 20232
-188.0%Return on equity2
0.00×Debt to equity2
-18.1M CHFFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development8¢1.3M CHF
  • Interest6¢949.0K CHF
  • Income tax86¢13.5M CHF

Out of 6.3M CHF in revenue.2 The company lost money this year.

Financial statements

Revenue526.3M CHF in 2023+41% since 2021
02.0M CHF4.0M CHF6.0M CHF8.0M CHF2021: 4.5M CHF4.5M CHF20212022: 7.1M CHF7.1M CHF2022+58%2023: 6.3M CHF6.3M CHF2023−11%
Operating income52-110.8M CHF in 2023+223% since 2021
-150.0M CHF-100.0M CHF-50.0M CHF02021: -34.3M CHF-34.3M CHF20212022: -52.0M CHF-52.0M CHF2022+52%2023: -110.8M CHF-110.8M CHF2023+113%
Net income52-98.2M CHF in 2023+183% since 2021
-100.0M CHF-75.0M CHF-50.0M CHF-25.0M CHF02021: -34.7M CHF-34.7M CHF20212022: -50.8M CHF-50.8M CHF2022+46%2023: -98.2M CHF-98.2M CHF2023+93%
Fiscal year2020202120222023
Revenue4.5M CHF57.1M CHF26.3M CHF2
Research and development19.0M CHF512.4M CHF21.3M CHF2
Operating income-34.3M CHF5-52.0M CHF2-110.8M CHF2
Interest1.3M CHF52.3M CHF2949.0K CHF2
Income before tax-35.5M CHF5-54.3M CHF2-111.7M CHF2
Income tax-820.0K CHF5-3.5M CHF2-13.5M CHF2
Net income-34.7M CHF5-50.8M CHF2-98.2M CHF2
Earnings per share-0 CHF/shares5-5 CHF/shares2-8 CHF/shares2
Earnings per share (diluted)-0 CHF/shares5-5 CHF/shares2-8 CHF/shares2
Shares (weighted, basic)3.6B shares510.6M shares211.8M shares2
Shares (weighted, diluted)3.6B shares510.6M shares211.8M shares2

Compare MindMaze Therapeutics Holding SA with another company

What it owns

What MindMaze Therapeutics Holding SA reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net397.0K CHF2 Dec 31, 202349.0K CHF2 Dec 31, 2022+710.2%
Operating-lease assets (leased space)2.6M CHF2 Dec 31, 20232.6M CHF2 Dec 31, 2022−2.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents14.6M CHF2 Dec 31, 202319.2M CHF2 Dec 31, 2022−24.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)54.4M CHF2 Dec 31, 2023162.9M CHF2 Dec 31, 2022−66.6%

Inventory

ItemLatestA year beforeChange
Inventory, total557.0K CHF2 Dec 31, 2023227.0K CHF2 Dec 31, 2022+145.4%

Former names

  • Relief Therapeutics Holding SAAug 25, 2021 to Mar 27, 20253
  • Relief Therapeutics Holding AGMar 30, 2021 to Mar 30, 20213

Filings

58 filings to the SEC since October 2021: 2 annual reports, 56 other. The latest 20:

  1. Apr 16, 2026424B3 EDGAR
  2. Mar 27, 2025F-6 POS FORM F-6 POST EFFECTIVE AMENDMENT NO. 4 TO REGISTRATION STATEMENT EDGAR
  3. Dec 17, 2024424B3 RULE 424(B)(3) ADR EDGAR
  4. Dec 17, 202415F-12G FORM 15-F NOTICE OF TERMINATION EDGAR
  5. Dec 16, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR DECEMBER, 2024 EDGAR
  6. Nov 12, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR NOVEMBER, 2024 EDGAR
  7. Nov 5, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR NOVEMBER, 2024 EDGAR
  8. Oct 28, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 EDGAR
  9. Oct 22, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 EDGAR
  10. Oct 9, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 EDGAR
  11. Oct 7, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 EDGAR
  12. Sep 23, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR SEPTEMBER, 2024 EDGAR
  13. Sep 19, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR SEPTEMBER, 2024 EDGAR
  14. Sep 4, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR SEPTEMBER, 2024 EDGAR
  15. Aug 30, 20246-K EDGAR
  16. Aug 6, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR AUGUST, 2024 EDGAR
  17. Jun 28, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR JUNE, 2024 EDGAR
  18. Jun 3, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR JUNE, 2024 EDGAR
  19. May 10, 20246-K FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR MAY, 2024 EDGAR
  20. Apr 30, 202420-F EDGAR

The 58 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How MindMaze Therapeutics Holding SA is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMindMaze Therapeutics Holding SA1
  • CIK0001854078
  • Filer statusNon-accelerated filer<br>emerging growth company1
  • Incorporated inSwitzerland1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressAvenue De Secheron 15, Ch-1202 Geneva, Switzerland1
  • Phone914-672-35551
  • Shares outstanding12,540,439 as of Dec 31, 20232
  • On EDGAR sinceMar 30, 20211
  • Filings60 in all: 6-K (34), 20FR12B/A (4), F-6 POS (4), 20-F (2), 424B3 (2), D (2), F-1/A (2), RW (2)1
    All 16 form types

    15F-12G (1), 20FR12B (1), 20FR12G (1), EFFECT (1), F-1 (1), F-6 (1), NT 20-F (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (20-F) Apr 30, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5